Yellow fever vaccine post-marketing surveillance in Brazil

Procedia in Vaccinology

Volumn 2, Issue 2, 2010, Pages 178-183

  Martins, Reinaldo de Menezes ^a   Maia, Maria de Lourdes de S ^a   Santos, Eliane Matos dos ^a   Cruz, Robson Leite de S ^a   dos Santos, Paulo Roberto G ^a   Carvalho, Sandra Maria Deotti ^a   Sato, Helena Keiko ^b   Schermann, Maria Teresa ^c   Mohrdieck, Renate ^c   Leal, Maria da Luz Fernandes ^a   Homma, Akira ^a  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b Immunizations Program   (Brazil)

^c Immunizations Program ^*  (Brazil)

Author keywords

Neurotropic disease; Post marketing surveillance; Serious adverse events; Viscerotropic disease; Yellow fever vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ANAPHYLACTIC SHOCK; ASEPTIC MENINGITIS; BRAZIL; BREAST FEEDING; CONFERENCE PAPER; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MENINGOENCEPHALITIS; MORTALITY; OPTIC NEURITIS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION;

EID: 77955116495     PISSN: 1877282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.provac.2010.07.012     Document Type: Conference Paper

References (21)

1. Santos C.N.D., Post P.R., Carvalho R., Ferreira I.I., Rice C.M., Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Research. 1995, 35:35-41.
2. Marchevsky R.S., Freire M.S., Coutinho E.S.F., Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 2003, 316:55-63.
3. Camacho L.A.B., Freire M.S., Leal M.L.F., Aguiar S.G., Nascimento J.P., Iguchi T., Lozana J.A., Farias R.H.G. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev. Saúde Pública. 2004, 38:671-678. and Collaborative Group for the Study of Yellow Fever Vaccines.
4. Galler R., Post P.R., Santos C.N.D., Ferreira I.I. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998, 16:1024-1028.
5. Camacho L.A.B., Aguiar S.G., Freire M.S., Leal M.L.F., Nascimento J.P., Iguchi T., Lozana J.A., Farias R.H.G. Reactogenicity of yellow fever vaccines in a randomized placebo-cntrolled trial. Rev. Saúde Pública. 2005, 39:413-420. and Collaborative Group for the Study of Yellow Fever Vaccines.
6. Galler R., Pugachev K.V., Santos C.L.S., Ocran S.W., Jabor A.V., Rodrigues S.G., Marchevsky R.S., Freire M.S., Almeida L.F.C., Cruz A.C.R., Yamamura A.M.Y., Rocco I.M., Travassos da Rosa E.S., Souza L.T.M., Vasconcelos P.F.C., Guirakhoo F., Monath T.P. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brasil. Virology 2001, 290:309-319.
7. Whittenbury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., Brinton M., Uchuya J., Gershman M., Toledo W., Staples E., Campos C., Martinez M., Chang G.J., Cabezas C., Lanciotti R., Zaki S., Montgomery J.M., Monath T., Hayes E. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27:5974-5981.
8. Engel A.R., Vasconcelos P.F.C., McArthur M.A., Barrett A.D.T. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006, 24:2803-2809.
9. Monath T.P., M.S. Cetron, D. E. Teuwen 2008. Yellow Fever Vaccine. In: Plotkin S., W. Orenstein, P. Offit (eds) Vaccines, 5th ed. Saunders, China, p. 959-1055.
10. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G.L., Soares R.C.R., Codeço C.T. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol. Infect. 2004, 132:939-946.
11. Vasconcelos P.F.C., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L.R.S., Monath T.P., Rodrigues S.G., Laval C., Costa Z.G., Vilela M.F.G., Santos C.L.S., Papaiordanou C.M.O., Alves V.A.F., Andrade L.D., Sato H.K., Rosa E.S.T., Froguas G.B., Lacava E., Almeida L.M.R., Cruz A.C.R., Rocco I.M., Santos R.T.M., Oliva O.F.P. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97. Reports from the Brazilian Ministry of Health. Reports from Brazilian State Health Secretaries. Reports from the Pharmacovigilance Unit, Clinical Advisory Unit, Bio-Manguinhos/Fiocruz.
12. Eidex R.B. History of thymoma and yellow fever vaccination (Letter to the editor). Lancet 2004, 364(9438):936.
13. Hoffacker V., Schultz A., Tiesinga J.J., Gold R., Schalke B., Nix W., Kiefer R., Müller-Hermelink H.K., Marx A. Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood. 2000, 96:3872-3879.
14. Silva M.L., Espirito-Santo L.R., Martins M.A., Silveira-Lemos D., Peruhype-Magalhães V., Caminha R.C., Maranhão-Filho P.A., Auxiliadora-Martins M.A., Martins R.M., Galler R., Freire M.S., Marcovistz R., Homma A., Teuwen D.E., Elói-Santos S.M., Andrade M.C., Teixeira-Carvalho A., Martins-Filho O.A. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. 2010, 17:118-126.
15. Martins R.M., Galler R., Freire M.S., Camacho L.A.B., Maia M.L.S., Homma A. Yellow fever vaccination: some thoughts on how much is enough (Letter to the Editor). Vaccine 2007, 25:10-11.
16. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., Cetron M.S. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263. and The Yellow Fever Vaccine Safety Working Group.
17. Lawrence G.L., Burgess M.A., Kass R.B. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun. Dis. Intell. 2004, 28:244-248.
18. Couto A.M., Salomão M.R., Schermann M.T., Mohrdieck R., Suzuki A., Carvalho S.M.D., Assis D.M., Araújo W.N., Flannery B. Transmission of yellow fever vaccine virus through breast-feeding - Brazil. MMWR. 2009, 59:130-132.
19. Santos A.P., Bertho A.L., Dias D.C., Santos J.R., Marcovistz R. Lymphocyte subset analyses in healthy adults vaccinated with yellow fever 17DD virus. Mem. Inst. Oswaldo Cruz. 2005, 100:331-337.
20. Neves P.C., Matos D.C.S., Marcovistz R., Galler R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 2010, 27:5543-5549.
21. Martins M.A., Silva M.L., Elói-Santos S.M., Ribeiro J.G.L., Peruhype-Magalhães V., Marciano A.P.V., Homma A., Kroon E.G., Teixeira-Carvalho A., Martins-Filho O.A. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 2008, 26:1173-1184.